Evidence map›Paper›PMID 29713784›Full record

SynthesisKnee surgery, sports traumatology, arthroscopy : official journal of the ESSKA2018

Limited evidence for adipose-derived stem cell therapy on the treatment of osteoarthritis.

Eoghan T Hurley, Youichi Yasui, Arianna L Gianakos, Dexter Seow, Yoshiharu Shimozono, Gino M M J Kerkhoffs, John G Kennedy

Open access · greenAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 5 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Eoghan T HurleyHospital for Special Surgery, 523 East 72nd Street, Suite 507, New York, NY, 10021, USA.
Youichi YasuiHospital for Special Surgery, 523 East 72nd Street, Suite 507, New York, NY, 10021, USA.
Arianna L GianakosHospital for Special Surgery, 523 East 72nd Street, Suite 507, New York, NY, 10021, USA.
Dexter SeowHospital for Special Surgery, 523 East 72nd Street, Suite 507, New York, NY, 10021, USA.
Yoshiharu ShimozonoHospital for Special Surgery, 523 East 72nd Street, Suite 507, New York, NY, 10021, USA.
Gino M M J KerkhoffsDepartment of Orthopaedic Surgery, Academic Medical Center, Amsterdam, The Netherlands.
John G KennedyHospital for Special Surgery, 523 East 72nd Street, Suite 507, New York, NY, 10021, USA. KennedyJ@hss.edu.
Hospital for Special Surgery · USAcademic Center for Evidence-Based Sports Medicine · NLKyoto University · JPRoyal College of Surgeons in Ireland · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this systematic review is to evaluate the effects of adipose derived mesenchymal stem cells (ADSCs) in the treatment of osteoarthritis (OA) in the clinical setting.

methodsA literature search was performed in the MEDLINE, EMBASE, and The Cochrane Library Database up to January 2017 for inclusion and exclusion criteria. Criteria for inclusion were clinical studies demonstrating the effects of ADSCs on OA, and written in English. The following variables were analyzed: donor site, volume of adipose tissue, preparation of ADSCs, clinical outcomes, and complication rate.

resultsSixteen studies (knee: 14 studies, multiple joints: 1 study, ankle: 1 study) were included in this systematic review. All of the studies prepared ADSCs in the form of the stromal vascular fraction (SVF). Inconsistencies between studies were found with regards to reported clinical variability, donor sites of SVF, and reported clinical outcomes. Nine studies used either platelet-rich plasma (PRP) (7/16) or fibrin (4/16) or both PRP and Fibrin (1/16), as an adjunct at time of SVF injection. All of the studies reported an improvement in clinical outcomes with the use of SVF. Five studies reported a 90% satisfaction rate, and no study reported any complications with liposuction. Five studies reported on complications, with a 5% incidence of swelling and pain.

conclusionsThis systematic review demonstrated that ADSCs are currently used in the form of SVF. While SVF may produce favorable clinical outcomes with minimal risk of side effects on osteoarthritis, the variability in the data and the use of biological adjuvants have confounded the effectiveness of ADSCs. This study will help surgeons understand the limitations in the literature on ADSCs. LEVEL OF EVIDENCE: Level IV, systematic review of level IV studies.

Indexed as

Stem Cell TransplantationAdipose TissueFibrinHumansOsteoarthritisPlatelet-Rich PlasmaFibrinAdipose-derived stem cellsCartilageOsteoarthritisSystematic review

Identifiers

PMID29713784
OpenAlexW2800835666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.